Behind inflated prescription prices, complicated insurance plans and dying local pharmacies, there is a little-known culprit: ...

Lansing's two hospitals and systems are charging very different prices for the same medications, a Michigan Health Purchasers ...

CMS draft guidance includes Medicare Part B drugs in 2026 price negotiations, with new prices set for 2028. Public comment period on CMS proposal is open until June 26, 2025. Ready to turn the ...

President Trump said Monday he will implement a prescription drug payment plan that could dramatically lower prices paid by Medicare and possibly Medicaid, although details remain murky.

Shares of Indian pharmaceutical companies plunged close to 6% on Monday after US President Donald Trump proposed sweeping price cuts on prescription drugs and pharma prices in the US, although ...

During his first term, Trump in 2020 had pushed a similar "most favored nation" rule for drug prices that would have applied to Medicare payments but was later rescinded by the Biden administration.

A new wave of Medicare drug ... nursing homes and assisted living communities. The expansion builds on previous negotiations covering 10 drugs, bringing the total to 25 medications subject to ...

Drugmakers raised the list prices on 575 name-brand drugs in just the first two days of the new year, according to drug price research firm 46brooklyn. Drugs for diabetes, HIV, cancer saw price ...

WASHINGTON — List prices for the 25 top Medicare Part D drugs not currently selected for Medicare drug price negotiation have increased by an average of 98 percent—or nearly doubled—since ...

The formulations for which ceiling prices have been revised include Salbutamol tablet 2 mg and 4 mg, Cefadroxil tablet 500 mg, and Lithium tablets 300 mg.(HT_PRINT) New Delhi: The National Drug ...

After many months of closely watched negotiations, the Centers for Medicare & Medicaid Services (CMS) announced the list of negotiated prices for 10 drugs. This marks the first set of negotiations ...

After a series of decisive court losses, the pharmaceutical industry appears to be taking its fight against Medicare drug price negotiations directly to the people—and the White House is not ...